Story

Novartis Stock Rebounds on Analyst Upgrades After Twin Trial Failures

ENTHMSVIIDZHZH-TWJAKOHI
Sep 10, 20262 min read
Novartis Stock Rebounds on Analyst Upgrades After Twin Trial Failures
Text size
Background

Novartis AG (NOVN) shares gained on Tuesday, staging a partial recovery after a steep sell-off triggered by two significant late-stage clinical trial failures. The rebound is being supported by a series of analyst rating changes as investors reassess the pharmaceutical giant's valuation following one of its worst single-day drops in over two decades.

Analyst Actions Provide Support

The stock's recovery was underpinned by several analyst notes that suggested the recent sell-off may have been overdone. According to Investing.com, HSBC upgraded Novartis to Hold from Reduce, arguing that the path of negative catalysts has now largely concluded following the trial setbacks.

Other investment banks also weighed in, helping to establish a new valuation floor for the stock:

  • HSBC: Upgraded to Hold and raised its price target to CHF 110 from CHF 95.
  • CLSA: Maintained its Outperform rating and CHF 135 target, highlighting the potential of other pipeline assets like remibrutinib.
  • RBC Capital: Initiated coverage with a Sector Perform rating and a CHF 120 target.
  • Citi: Maintained its Buy rating, though it trimmed its price target to CHF 135.

The Catalyst for the Sell-Off

Sample IUX Markets – In-articleAd

The rebound follows a sharp plunge on September 8 after Novartis announced back-to-back failures in its late-stage pipeline, erasing billions of francs in market value. The first disappointment came from del-desiran, which missed its primary endpoint in the HARBOR study for myotonic dystrophy type 1.

This was compounded by the failure of pelacarsen in the cardiovascular Lp(a)HORIZON outcomes study. The dual setbacks raised significant concerns among investors about the company's pipeline execution and its strategy for targeting lipoprotein(a), or Lp(a).

Market Reaction and Outlook

In Tuesday's trading session, Novartis shares rose 1.3% to close at CHF 113.14. The move was aided by a modestly positive tone in the broader equity markets, which had been weighed down by the Novartis-led decline in the prior session.

Despite the partial recovery, questions surrounding the company’s long-term growth prospects and the viability of its research and development strategy persist. Investors will be closely watching for updates on other key assets in the company's pipeline.

Read next

More on Stocks
Back to latest news

LATEST